Product image of Linelle Diario (Ethinylestradiol, Levonorgestrel | Lactose Anhydrous) supplied by GNH India

Linelle Diario

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose Anhydrous
Origin:
EU

Linelle Diario (Ethinylestradiol, Levonorgestrel | Lactose Anhydrous)

Ethinylestradiol and Levonorgestrel, the active ingredients in Linelle Diario, are a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH India supplies Linelle Diario as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Theramex Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linelle Diario, a combined oral contraceptive, is used within the hormonal regulation pathway to prevent unintended pregnancy.

  • Contraception: prevents pregnancy in women of childbearing potential.
  • Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.
  • Acne management: may reduce moderate acne associated with hormonal fluctuations.

How It Works

  • Ethinylestradiol and levonorgestrel act together to suppress the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol provides estrogenic feedback that reduces follicle‑stimulating hormone (FSH) release, while levonorgestrel, a progestogen, inhibits luteinizing hormone (LH) surge, preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating an environment unfavorable for sperm penetration and implantation.

Side Effects

Linelle Diario may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: temporary swelling or discomfort.
  • Headache: occasional tension‑type headache.
  • Breakthrough bleeding: spotting between periods.
  • Mood changes: mild irritability or mood swings.
  • Weight fluctuation: slight increase or decrease.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Arterial thrombosis: stroke or myocardial infarction.
  • Severe hypertension: sudden rise in blood pressure.
  • Liver tumor: benign hepatic adenoma.
  • Anaphylaxis: rare severe allergic reaction.

Precautions & Warnings

Before prescribing Linelle Diario, clinicians should consider several precautionary measures to ensure safe use.

  • Cardiovascular risk assessment: evaluate history of thromboembolic disease or smoking.
  • Hepatic function review: contraindicated in severe liver impairment.
  • Smoking cessation: advise women over 35 to stop smoking.
  • Drug interaction check: identify concurrent enzyme‑inducing agents.
  • Pregnancy confirmation: ensure patient is not pregnant before initiation.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Linelle Diario can interact with other medicines, affecting its contraceptive efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce hormone levels.
  • Antiretroviral protease inhibitors (e.g., ritonavir): can increase hormone concentrations and risk of side effects.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., ketoconazole, itraconazole): may increase plasma hormone levels.
  • St. John’s Wort: may lower contraceptive effectiveness.
  • Certain antibiotics (e.g., tetracycline, metronidazole): minimal effect but monitor for breakthrough bleeding.

Frequently Asked Questions

Linelle Diario is a combined oral contraceptive containing ethinyloestradiol and levonorgestrel. It is prescribed to prevent unintended pregnancy in women of reproductive age by inhibiting ovulation and creating conditions that are unfavorable for fertilisation and implantation.

Ethinyloestradiol provides estrogenic feedback that suppresses follicle‑stimulating hormone, while levonorgestrel, a progestogen, blocks the luteinising hormone surge needed for ovulation. Together they also thicken cervical mucus and alter the endometrial lining, reducing the chance of sperm entry and implantation.

The dosing regimen for Linelle Diario is determined by the prescribing clinician. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule should follow the healthcare provider’s instructions.

Linelle Diario must not be used during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. During breastfeeding, the benefit‑risk profile should be evaluated by a healthcare professional, as hormonal contraceptives can affect milk production and infant exposure.

To order Linelle Diario, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linelle Diario contains the standard dose combination of ethinyloestradiol and levonorgestrel, which is comparable to many other COC products. Its efficacy, safety profile and side‑effect spectrum are similar to other second‑generation progestogen‑containing pills, though individual tolerability may vary.

Linelle Diario tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Linelle Diario is taken orally, usually as a single tablet each day at the same time. The typical regimen includes 21 consecutive active tablets followed by a hormone‑free interval, but patients should follow the specific instructions provided by their prescriber.

Serious risks include venous or arterial thromboembolism, severe hypertension, hepatic adenoma, and rare allergic reactions such as anaphylaxis. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Linelle Diario is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumours, active thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are known to be hypersensitive to any of its components.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose Anhydrous

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT